Elk Grove Village, IL – According to filings with the U.S. Securities and Exchange Commission, Coordination Pharmaceuticals is raising $22,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Wenbin Lin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Coordination Pharmaceuticals
Coordination Pharmaceuticals, Inc. (CPI), is a privately held immuno-oncology company founded to develop anticancer products that can address unmet medical needs and improve patient care. Our proprietary nanoscale coordination polymer (NCP) platform combines synergistic therapeutics to specifically target solid tumors, increasing efficacy while simultaneously reducing toxicity. The NCP platform was pioneered by the lab of Professor Wenbin Lin at the University of Chicago. As a versatile technology platform, NCP components can be purposefully chosen to synergize with and enhance currently existing therapies. CPI products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.

To learn more about Coordination Pharmaceuticals, visit http://www.coordinationpharma.com/

Contact:
Wenbin Lin, Chief Executive Officer
847-298-2436
wenbin.lin@coordinationpharma.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved